Recent news coverage includes Forian being highlighted in a Berkshire Hathaway stock purchase list and various market and industry developments.

• Forian was noted among stocks purchased by Berkshire Hathaway in its first quarter without Warren Buffett as CEO, indicating investor interest in the company [N1].
• Market conditions remain mixed amid geopolitical tensions, with no direct impact reported on Forian [N2].
• General market and retirement planning articles mention broader economic themes but do not specifically address Forian [N3].
• No recent news directly related to Forian's operational or financial developments beyond the Berkshire Hathaway mention [N1].

Forian's proprietary analytics platform and data management solutions address critical needs in healthcare and financial services, sectors with growing demand for data-driven insights. The company's acquisition of Kyber Data Science enhances its capabilities and customer base. Strong liquidity and a diversified revenue base primarily in the U.S. support operational stability. Continued investment in R&D and sales and marketing may enable the company to expand its product offerings and market reach. The company's strategic review and unsolicited offer to take it private indicate potential interest from investors recognizing its value.

Forian faces risks from vendor data licensing changes, including a key vendor exiting the data licensing business, which may impact the availability and cost of data critical to its products. Contract terminations with health science customers have contributed to recent revenue declines. The company has reported net losses and negative operating cash flow in recent periods. Dependence on a limited number of large customers and the need to secure alternative data sources on favorable terms pose ongoing challenges. Strategic review expenses and potential changes in ownership may introduce uncertainty.

Forian's moat is based on its proprietary data management capabilities and analytics solutions tailored to healthcare, life sciences, and financial services industries. The company's ability to integrate and analyze complex data sets, combined with its established customer relationships and ongoing investments in product development, supports its competitive position. However, reliance on third-party data vendors and the need to secure comparable data sources present challenges. The company's specialized expertise and data assets create barriers to entry for competitors, but ongoing vendor and market risks require active management.

• Vendor Data Licensing Risk: A key information vendor announced exit from the data licensing business by end of 2026, requiring Forian to find alternative data sources. There is no assurance that comparable data can be obtained on similar terms, which could impact product offerings and costs.
• Customer Concentration and Contract Terminations: Recent revenue decreases are partly due to contract terminations with health science customers. Dependence on a limited number of large customers may expose the company to revenue volatility.
• Operating Losses and Cash Flow: The company reported a net loss of $3.36 million for Q1 2026 and used cash in operating activities. Continued losses and cash burn may affect financial flexibility.
• Strategic Review and Acquisition Uncertainty: Professional fees related to an unsolicited offer to take the company private indicate potential ownership changes, which may create operational and strategic uncertainty.

• Forian Inc. was incorporated in Delaware on October 15, 2020, as a wholly owned subsidiary of Forian LLC for the purpose of effecting a business combination with Helix Technologies, Inc.
• The company provides a suite of data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in healthcare, life sciences, and financial services industries.
• On January 8, 2026, Forian redomiciled from Delaware to Maryland; this did not change its business, management, or operations.
• On April 2, 2026, Forian entered into an Agreement and Plan of Merger with 2025 Acquisition Company, LLC and Bravo Merger Sub, Inc.
• Revenues are derived from fees for proprietary information products and services, recognized as products are updated.
• Sales for the three months ended March 31, 2026, were 99% United States and 1% Great Britain/others.
• Cost of revenues includes labor costs, information licensing, hosting and infrastructure costs, and client service team costs.
• A key vendor announced exit from data licensing business by end of 2026, prompting Forian to seek alternate data sources; the company is evaluating contract rights and impact on future obligations.
• Research and development expenses primarily consist of employee-related expenses, subcontractor and consulting fees, and hosted infrastructure costs, focused on adding new features and applications.
• Sales and marketing expenses include salaries, commissions, marketing programs, advertising, market research, and events; the company plans to continue investing in these areas.
• General and administrative expenses include salaries, benefits, professional fees, legal, accounting, and other corporate expenses.
• Strategic review and acquisition related expenses in Q1 2026 relate to professional fees for an unsolicited offer to take the company private.
• For the three months ended March 31, 2026, revenues were $6.85 million, a decrease from $7.06 million in the prior year period, mainly due to contract terminations in health science customers, partially offset by new customer growth.
• Cost of revenues increased to $4.84 million from $3.13 million year-over-year, primarily due to higher information licensing and processing expenses, reducing gross margin to 29% from 56%.
• Research and development expenses increased to $961,458 from $606,237 year-over-year due to more employees.
• Sales and marketing expenses increased slightly to $1.48 million from $1.38 million, due to higher employee-related expenses.
• General and administrative expenses decreased to $2.45 million from $3.28 million, mainly due to lower stock compensation expense.
• Interest and investment income decreased to $155,543 from $328,848, reflecting lower interest rates.
• Interest expense was zero in Q1 2026, down from $52,678 in Q1 2025, due to redemption of convertible notes.
• Net loss for Q1 2026 was $3.36 million compared to $1.13 million in Q1 2025.
• Liquidity as of March 31, 2026, included cash and equivalents of $30.95 million, current assets of $37.41 million, and current liabilities of $11.93 million, resulting in a current ratio of 3.14 and a cash ratio of 2.6.
• The company has no outstanding convertible notes as of March 31, 2026, following redemption of prior notes maturing September 1, 2025.
• Net cash used in operating activities was $547,986 for Q1 2026, a decrease compared to cash provided by operating activities of $448,180 in Q1 2025, due to decreased revenues, increased costs, and strategic review expenses.
• Net cash provided by investing activities was $18.67 million in Q1 2026, mainly from sales of marketable securities.
• Net cash used in financing activities was $78,587 in Q1 2026, lower than prior year due to changes in tax payments related to vested restricted stock units.
• The company acquired Kyber Data Science, LLC effective October 31, 2024, accounted for as an acquisition with Forian as the accounting acquirer.
• The company has a full valuation allowance on deferred tax assets due to a history of operating losses.
• The company uses Adjusted EBITDA as a non-GAAP measure to evaluate performance, excluding items such as depreciation, stock-based compensation, interest expense, and strategic review expenses.
• The company faces risks related to vendor data licensing changes, contract terminations, and the ability to obtain comparable data on similar terms.
• The company plans to continue funding operations and acquisitions through operating cash flow, available cash, debt financing, and equity issuances.